Key Points
Canopy Growth's balance sheet has improved considerably in recent years, but at the cost of heavy share dilution.
Still, while results have yet to sufficiently improve, a recently completed merger could change the story.
- 10 stocks we like better than Canopy Growth ›
Canopy Growth (NASDAQ: CGC) has made considerable efforts to turn itself around. Over the past few years, the Canada-based cannabis company has significantly reduced its outstanding debt. It has also stacked up considerable cash.
Yet while Canopy is less indebted and more liquid than before, this recapitalization came at the cost of share dilution. Worse yet, while the balance sheet has improved, profitability, even on an EBITDA (earnings before interest, taxes, depreciation, and amortization) basis, remains elusive. With this, uncertainty runs high, but a recent merger could change the story for Canopy, still one of the most-followed marijuana stocks.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
Canopy and its continued dilution spiral
Over the past five years, Canopy Growth shares have declined by over 99.5%. In other words, a $10,000 investment made in May 2021 would be worth less than $50 today. The key reason for this severe destruction of shareholder value was the company's continued string of losses, coupled with Canopy's use of dilutive financing to cover them.
Even as losses narrowed, Canopy has continued to tap equity markets, diluting the stock's underlying value. The last big capital raise happened last August. That's when Canopy Growth raised $200 million through an at-the-market (ATM) equity program.
Canopy issued new shares and sold them on the open market. Again, this may have strengthened the balance sheet, but it has resulted in further severe losses for existing shareholders.
What could change the story?
Sometimes, share dilution can be worth it if the cash is used to improve a company's underlying performance. Yet while Canopy Growth has stabilized losses, the company still struggles with reaching profitability, even on an EBITDA basis.
That said, this could soon all change, and not necessarily because of possible external catalysts like U.S. federal legalization. Last March, Canopy completed its acquisition of MTL Cannabis. This merger could create millions in run rate cost synergies.
Canopy also plans to use MTL's production capacity to meet international demand for medical marijuana. Still, it may prove best to stay on the sidelines until Canopy's next quarterly earnings release on May 29. That day, the company could unveil better-than-expected results and provide further guidance on its path to profitability.
Should you buy stock in Canopy Growth right now?
Before you buy stock in Canopy Growth, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Canopy Growth wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $468,861!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,445,212!*
Now, it’s worth noting Stock Advisor’s total average return is 1,013% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of May 15, 2026.
Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
